173 related articles for article (PubMed ID: 36649280)
1. Postoperative radiotherapy timing, molecular subgroups and treatment outcomes of Thai pediatric patients with medulloblastoma.
Jaruthien T; Nantavithya C; Santisukwongchote S; Shuangshoti S; Techavichit P; Sosothikul D; Amornfa J; Shotelersuk K
PLoS One; 2023; 18(1):e0271778. PubMed ID: 36649280
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma: Distinctive Histo-Molecular Correlation with Clinical Profile, Radiologic Characteristics, and Surgical Outcome.
Narayan V; Sugur H; Jaiswal J; Arvinda HR; Arivazhagan A; Somanna S; Santosh V
Pediatr Neurosurg; 2019; 54(5):329-340. PubMed ID: 31480064
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
6. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
7. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
8. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
9. Pediatric medulloblastoma in the molecular era: what are the surgical implications?
Kameda-Smith MM
Cancer Metastasis Rev; 2020 Mar; 39(1):235-243. PubMed ID: 32095940
[TBL] [Abstract][Full Text] [Related]
10. The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases.
Wu T; Qu PR; Zhang S; Li SW; Zhang J; Wang B; Liu P; Li CD; Zhao F
Sci Rep; 2020 Jun; 10(1):9769. PubMed ID: 32555264
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma.
Chin AL; Moding EJ; Donaldson SS; Gibbs IC; Soltys SG; Hiniker SM; Pollom EL
Neuro Oncol; 2018 Jul; 20(8):1133-1141. PubMed ID: 29309676
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
13. [Medulloblastoma].
Yamaguchi S; Fujimura M
No Shinkei Geka; 2023 Sep; 51(5):858-866. PubMed ID: 37743337
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
Eid AM; Heabah NAE
J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
[TBL] [Abstract][Full Text] [Related]
15. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract][Full Text] [Related]
16. Molecular Classification of Medulloblastoma.
Kijima N; Kanemura Y
Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A
J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of microRNA-125a expression status in molecular groups of pediatric medulloblastoma.
Hamam SM; Abdelzaher E; Fadel SH; Nassra RA; Sharafeldin HA
Childs Nerv Syst; 2023 Jul; 39(7):1869-1880. PubMed ID: 36892621
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma.
Li K; Duan WC; Zhao HB; Wang L; Wang WW; Zhan YB; Sun T; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZF; Zhang ZY
Sci Rep; 2019 Sep; 9(1):13239. PubMed ID: 31519974
[TBL] [Abstract][Full Text] [Related]
20. [Craniospinal radiotherapy in combined therapy of medulloblastoma in children and adolescents].
Golubicić I; Bokun J; Nikitović M; Mladenović J; Sarić M; Bekić Z
Srp Arh Celok Lek; 2003; 131(5-6):226-31. PubMed ID: 14692129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
